This real-world study sheds light on the clinical outcomes of patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD–TPI). Conducted across Spain and Italy, the study evaluated 26 patients, offering valuable insights into survival outcomes and treatment-related adverse events in routine clinical practice.
Key findings reveal that the median overall survival was 6.6 months, with patients demonstrating good prognostic characteristics achieving longer survival (7.6 months) compared to those with poor prognostic profiles (4.2 months). Notably, patients with an ECOG performance status of 0 experienced the highest survival rates, reaching up to 12 months. Despite the modest efficacy, FTD–TPI proved to be a viable option, with manageable toxicity profiles.
This study emphasizes the importance of personalized treatment strategies, especially for high-risk subgroups like BRAF-mutant mCRC, and highlights the critical role of real-world evidence in shaping future clinical decisions.
